BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
Cadila Healthcare Ltd.'s revenue declined 0.9% YoY (down 6.0% QoQ) to Rs 37.85 billion.
It was due to 12.0% YoY rise in India revenue, 12.0% YoY decline in the U.S. revenue, 48.0% YoY increase in emerging market’s revenue, 12.0% YoY increase in Europe revenue, 179.0% YoY increase in alliances and other’s revenue, and 16.0% YoY decline in active pharma ingredient revenue in Q2 FY22.
Cadila Healthcare' gross profit margin contracted by 191 basis points YoY to 63.5%.
Contraction in gross profit margin was partially offset by strong growth in India and emerging markets and led to marginal improvement in Ebitda margins YoY.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR